At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,187 enrolled
Drug / intervention
Bazedoxifenedrug
Likely dose
Bazedoxifene 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Viviant®20mg Special Investigation (Regulatory Post Marketing Commitment Plan)
In Brief
An observational study evaluating Bazedoxifene for Osteoporosis. Completed, enrolled 3,187 participants.
Detailed Summary
In this survey, to collect the safety and efficacy information of Bazedoxifene in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedNov 2011
Primary CompletionJun 2016
TodayJul 2026
First PostedNov 11, 2011
Enrollment StartNov 1, 2011
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 14.6 years ago
Interventions
Bazedoxifenedrug
For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.